About

Elyse is a sought-after analyst and deep domain biotech and medtech analyst. With a particular interest in projects backed by science and medicine, she provides advice to fund managers on their healthcare investments. With strong US–Australia connections, Elyse has worked alongside companies at all stages through pre-IPO, IPO and their listed lives. Her experience is informed by roles as a healthcare analyst for Canaccord Genuity, Bell Potter, Wilsons in Melbourne Australia. Prior to this, Elyse worked as a biotechnology equity research associate at Cowen & Company, New York, New York. As an adviser and equities analyst for small and mid cap companies ($100m-$2b), Elyse has steered a wide range of Australian startups and scale-ups. Elyse’s philosophy is grounded in real solutions for real problems, assessing probability for regulatory and commercial success, and accountability for shareholder capital. Within the health sector she is a strong proponent of value-based care, which links clinical and technological investment to ongoing clinical improvement. As markets evolve, they continually re-frame opportunity. The potential Elyse sees is a new scope to align profit for corporates and investors with human benefit – returns deriving from response to need rather than exploitation of vulnerability.